Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Sarepta Therapeutics cuts one-third of its workforce and pauses drug programs after safety concerns over its gene therapy.
Sarepta Therapeutics, a biotech firm, is cutting its workforce by around 500 employees, or a third of its staff, and will pause several drug programs to save over $400 million annually.
This move follows safety concerns over its Duchenne muscular dystrophy gene therapy, Elevidys, after two patient deaths.
The company will add a black box warning for liver failure risk and is working on a new immune-suppressing regimen for the therapy.
5 Articles
Sarepta Therapeutics recorta un tercio de su fuerza de trabajo y suspende los programas de medicamentos después de las preocupaciones de seguridad sobre su terapia génica.